Rituximab Treatment as Second-Line Therapy in Glucocorticoid Nonresponsive Graves' Orbitopathy: A Nonrandomized, Controlled, Interventional Study
Switch to RTX early in the treatment course did not result in better CAS or QoL, compared to continuous intravenous glucocorticoids.
Authors
- Mats Holmberg (ORCID: https://orcid.org/0000-0003-2884-9981)
- Helena Filipsson Nyström (ORCID: https://orcid.org/0000-0002-4670-3401)
- Helge Malmgren
- Sofia Manousou (ORCID: https://orcid.org/0000-0002-7965-0772)
- Elin Ekdahl
Institutions
- Karolinska University Hospital (SE)
- Sahlgrenska University Hospital (SE)
- Karolinska Institutet (SE)
- Södra Älvsborg Hospital (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Endocrine Practice
- Published
- 2024-12-12
- DOI
- https://doi.org/10.1016/j.eprac.2024.12.007
- Citations
- 2
- Primary Topic
- Ophthalmology and Eye Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Ögonfonden
- Göteborgs Läkaresällskap
- Sahlgrenska Universitetssjukhuset
- Göteborgs Universitet